ImmunityBio Shares Jump After First Patients Dosed in Phase 1 Study for Potential Non-Hodgkin's Lymphoma Treatment
MT Newswires Live00:20
ImmunityBio (IBRX) shares were rallying 40% Friday after the company said Thursday it dosed the first patients in a phase 1 trial that will assess its CAR-NK cellular therapy as a potential treatment for non-Hodgkin's lymphoma.
The Quilt 106 trial will initially use CD19-targeted high-affinity natural killer cells alone and, if proven safe, will combine them with rituximab for patients with certain CD19+ and CD20+ relapsed B-cell non-Hodgkin's lymphoma, the company said.
The phase 1 study will involve up to 10 participants and take place in three South African cities, it added.
ImmunityBio said it expects to complete patient enrollment by Q1 2025, with initial trial results anticipated in H2.
Price: 5.89, Change: +1.68, Percent Change: +39.90
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
